Source: International Congress 2017 – Novel and old entities
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. O'Mahony (Co. Cork, Ireland). Identifying Inflammatory Myopathies to optimise Interstitial lung disease treatment strategies>. 3839

Member's Comments

No comment yet.

Related content which might interest you: Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy Source: International Congress 2014 – ILDs 4 Year: 2014 Aetiological panorama in the diagnosis of interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Childhood diffuse parenchymal lung diseases: Diagnosis, treatment and outcome Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Statin-induced lung diseases Source: International Congress 2016 – Sarcoidosis Year: 2016 Markers of injury and fibrosis in occupational interstitial lung diseases (OILD) Source: International Congress 2015 – Occupational disease: clinical cases and series Year: 2015 Factors predicting resolution in nitrofurantoin-induced lung disease Source: International Congress 2016 – Orphan diseases II Year: 2016 Antisynthetase syndrome related interstitial lung disease may have a better treatment response than other forms of Idiopathic Inflammatory Myopathies: a multi-national study Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Does CRP predicts severity of hospitalized patients with diffuse interstitial lung disease? Source: International Congress 2014 – ILDs 5 Year: 2014 Childhood interstitial lung disease: A diagnostic challenge Source: International Congress 2015 – Connective tissue disorders Year: 2015 Interstitial lung disease: improving classification and prognosis Source: Virtual Congress 2021 – Clinical year in review Year: 2021 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Biomarkers for interstitial lung disease Source: International Congress 2016 – ME1 Biomarkers for interstitial lung disease Year: 2016 Pregnancy course in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 HCMV infection triggers the development of interstitial lung diseases in autoimmune disorders Source: International Congress 2014 – IPF and surroundings Year: 2014 Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Multidisciplinary board for interstitial lung disease: Relevance for real life? Source: International Congress 2015 – New insights into IIPs Year: 2015 Chronic hypersensitivity pneumonitis: Is the interstitial pneumonias disease behavior classification suitable for outcome stratification? Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options Year: 2021